

5 & 6 FEBRUARY 2018 | ETC. VENUES | 200 ALDERSGATE | LONDON

4TH
ANNUAL

600⁺
ATTENDEES

250
INVESTORS &
PHARMA

100⁺
SPEAKERS

50⁺
SHOWCASES



EUROPE'S LEADING LIFE SCIENCE
INVESTMENT AND PARTNERING CONGRESS

PLATINUM PARTNERS

GOLD PARTNERS



ALLEN & OVERY



Cooley

COVINGTON



JAG SHAW
BAKER

LEERINK

N+1 SINGER



Seroba.
*Investing in life sciences.
Investing in life.*



VINGE

WHITE & CASE

CORPORATES, INVESTORS AND PHARMA... THE WORLD CONGRESS IN 2018!



BRINGING DEALS TO LIFE

Welcome to the 4th annual Biotech and Money / Medtech and Money World Congress.

With our relentless focus on quality peer-to-peer discussion, high-level networking and partnering, unique formats and a vetted, high-calibre audience, we bring together the people that matter to the future of healthcare and life science funding, finance, investment and deal making.

For 2018 we're excited to bring you a number of new additions to the content and formats, and with 1-2-1 partnering running the length of the congress, it's an eventful two days.

We're delighted that you've chosen to join us for our biggest event to date. We wish you an incredible event.

The World Congress Team

Wifi network: etcvenues | Wifi code: wifi8028

KEY FEATURES OF THE WORLD CONGRESS

- 1** KEYNOTE SESSIONS WITH LEADING LIFE SCIENCE EXECUTIVES AND FUNDS
- 2** TRACKS THAT COVER BOTH BIOTECH AND MEDTECH IN EQUAL MEASURE
- 3** PANEL DISCUSSIONS TACKLING EARLY, GROWTH AND LATE-STAGE INVESTMENT STRATEGIES
- 4** INTERACTIVE ROUNDTABLES WITH PHARMA LEADERS (P.11)
- 5** 'ANATOMY OF...' CASE STUDIES FROM INDUSTRY'S GREATEST SUCCESS STORIES
- 6** INV€\$TABLE SHOWCASES FROM OVER 50 INNOVATIVE BIOTECH AND MEDTECH COMPANIES (P.19)
- 7** PRE-EVENT 1-2-1 PARTNERING SYSTEM TO SEARCH, QUALIFY AND ARRANGE ON-SITE MEETINGS (P.4)
- 8** A GLOBAL CONFERENCE WITH ATTENDANCE FROM 20+ COUNTRIES

WHAT'S NEW IN 2018

- 1** EXCLUSIVE LAUNCH OF THE 2ND EDITION OF THE LIFE SCIENCE INVESTOR PERCEPTION REPORT
- 2** CHATHAM HOUSE RULE FORUMS FOR LISTED COMPANY CEOs FROM THE UK, EUROPE AND NORDICS (P.8 & P.9)
- 3** INTIMATE IP, IPO AND M&A WORKSHOPS FOR EXECUTIVES
- 4** EXCLUSIVE MEDTECH SHARK TANK SESSION TO PRESENT TO COMMERCIAL LEADERS (P.11)

AGENDA AT A GLANCE - DAY 1



KEYNOTE: EUROPEAN CAPITAL MARKETS: LEVERAGING LARGER CAPITAL POOLS
KEYNOTE: US-EURO TRANSATLANTIC VALUE CREATION AND INVESTMENT
KEYNOTE: SOVEREIGN WEALTH FUNDS AND HEALTHCARE



Inv€stable



TECH TRANSFER AND
TRANSLATING
INNOVATION

COMMERCIAL
STRATEGIC INVESTMENT
IN MEDTECH

42 INNOVATIVE BIOTECH
AND MEDTECH
COMPANIES PITCH THEIR
RESEARCH, TECHNOLOGY,
FUNDRAISING AND
PARTNERING
REQUIREMENTS

A Chatham House Rule, invite-only
forum for CEOs, CFOs and chairmen of
listed and soon-to-be listed **UK**-based
life science and healthcare companies.

SEED FUNDING FOR
BIOTECH DEVELOPMENT

PAN-EUROPEAN MEDTECH
SEED FUNDING

GROWTH FINANCE
ENVIRONMENT IN
BIOTECH

MEDTECH VENTURE
INVESTOR PANEL

BUILDING BIOTECH
COMPANIES WITH SCALE

FUNDING AR, AI & VR
START-UPS TO GROWTH

CORPORATE VENTURE
APPETITE

EARLY STAGE PHARMA
COLLABORATION

NEW FUNDS ON THE
BLOCK

EIB QUASI EQUITY
INVESTMENTS



A Chatham House Rule, invite-only
forum for CEOs, CFOs and chairmen
of listed and soon-to-be listed **France**,
BENELUX, **DACH**, **Italy** and **Spain**-
based life science and healthcare
companies.



A Chatham House Rule, invite only
forum for CEOs, CFOs and chairmen of
listed and soon-to-be listed **Sweden**,
Denmark, **Finland** and **Norway**-based
life science and healthcare companies.



THERAPEUTIC
ROUNDTABLES

MEDTECH SHARK TANK

IP Workshop is an intimate forum for
life science executives requiring
guidance on the correct way to
approach IP and patent protection
issues.

Biotech and Money is teaming up with
some of the world's foremost experts,
advisers, bankers and consultants to
help CEOs and CFOs navigate the how,
what, where and when of a successful
cross-border M&A.

CLOSING FIRESIDE CHAT:
IN CONVERSATION WITH...THE INTERSECTION OF DATA-DRIVEN PRODUCTS AND HEALTHCARE

AGENDA AT A GLANCE - DAY 2



IN CONVERSATION WITH...
BIOTECH MEGA DEALS

PHARMA CORPORATE AND
BUSINESS
DEVELOPMENT

ANATOMY OF A...
PRIVATE
FINANCE RAISE

ANATOMY OF A...
HYBRID
BUSINESS MODEL

ANATOMY OF A...
LICENSING DEAL

ANATOMY OF AN...IPO



IN CONVERSATION WITH...
MEDTECH MEGA DEALS

COMMERCIAL LEADER BD,
M&A AND
TRANSACTIONS

ANATOMY OF A...
PRIVATE FINANCE RAISE

ANATOMY OF AN...IPO

HI-GROWTH / DEAL
MAKING MEDTECH /
DEVICE COMPANY

Investable

12 INNOVATIVE BIOTECH
AND MEDTECH / DEVICE
COMPANIES PITCH THEIR
RESEARCH, TECHNOLOGY,
FUNDRAISING AND
PARTNERING
REQUIREMEN



Biotech and Money is teaming up with some of the world's foremost experts, advisers, bankers and consultants to help CEOs and CFOs navigate the how, what, where and when of a successful **Nasdaq / US IPO**.

CLOSING PANEL:
TRACKING THE INDUSTRY TRENDS

1-2-1 PARTNERING



The Congress provides dedicated out of session networking time to hold those all important face-to-face meetings. To ensure you maximise this time, we've provided attendees with access to Meeting Mojo, the congress 1-2-1 partnering app, to create an online profile and book meetings.

Meetings arranged through Meeting Mojo will be allocated a table within **CREATIVE 1**, which is a dedicated room located within the congress venue. Head to the 1-2-1 Desk to pick up your meeting schedule and follow the on-site signs for the 1-2-1 Partnering tables.

Login at: <http://world-congress.meeting-mojo.com/>

Informal meeting space is located in the main congress atrium for meetings not arranged through Meeting Mojo.



250+
INVESTORS

85%
VC, CVC &
FUNDS

15%
ANGELS, HNW
& FAMILY
OFFICE

£1-5M
AVERAGE MIN.
INVESTMENT
LEVEL

£5-10M
AVERAGE MAX.
INVESTMENT
LEVEL

SEED,
EARLY,
GROWTH,
LATE-GROWTH
& LISTED
FOCUS

1200+
ONSITE
MEETINGS

600+ **80%** **72%**

ATTENDEES
ACROSS THE
TWO DAYS

CORPORATE,
INVESTOR AND
PHARMA

C-LEVEL AND
SENIOR
MANAGEMENT

2018 KEY STATS

DAY 1 - MONDAY 5TH FEBRUARY 2018

8.00

REGISTRATION, BREAKFAST AND 1-2-1 PARTNERING

9.00

WELCOME REMARKS

Neil Darkes, Co-CEO, Biotech and Money

9.10

OPENING KEYNOTE PANEL:

EUROPEAN CAPITAL MARKETS: LEVERAGING LARGER CAPITAL POOLS

As the healthcare sector continues to develop favourably, what can the UK and Europe be doing better (or more of) to see a more sustained or increased capital flow? Prominent UK and EU investment fund executives and stakeholders share the stage to outline their views, challenges and opportunities within life science investment in the year ahead.

Moderator: Clive Cookson, Science Editor, Financial Times

Chandra P. Leo, Investment Advisor, HBM Partners

Sander Slootweg, Managing Director, Forbion Capital Partners

Hubert Birner, Managing Partner, TVM Capital Life Science

Tim Haines, Managing Partner, Abingworth

Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners

Mårten Steen, Partner, HealthCap

PREMIUM 1, 2 & 3

9.50

KEYNOTE PANEL:

US-EURO TRANSATLANTIC VALUE CREATION AND INVESTMENT

In this high level discussion, we assemble a panel of leading US investment funds and their executives to debate the key issues surrounding investing in Europe, their role providing a bridge to enable European companies to access US capital markets, and for North American companies to have access to Europe for development, expansion and access to innovation.

Moderator: Clive Cookson, Science Editor, Financial Times

Kate Bingham, Managing Partner, SV Health Investors

Johnston Erwin, VP, Corporate Business Development, Eli Lilly & Co.

Joe Anderson, CEO, Aris Bioscience plc

Martin Murphy, CEO, Syncona Ltd

David Berry, General Partner, Flagship Pioneering

10.30

IN CONVERSATION WITH...

SOVEREIGN WEALTH FUNDS, PE AND HEALTHCARE

In this 'In conversation with...' we discuss the appetite by Sovereign Wealth Funds to take longer-term tilts towards private markets and in particular healthcare and life sciences. We discuss rationale behind sovereign investment funds' managed vs direct investment strategies, what roles they see themselves playing, the growing demand by SWFs for seeking out earlier stage investments and what that means for private equity and venture capital funds.

Moderator: Tom Whelan, Head of Private Equity, Hogan Lovells

Paul Saunders, Head of Innovation Investments, Ireland Strategic Investment Fund

10.50

VIRTUOUS CIRCLES: WHERE THE MONEY WENT IN 2017

John Hodgson, Data Editor, Pharma, SCRIP Pharma Intelligence

11.00

MORNING REFRESHMENTS AND 1-2-1 PARTNERING

11.30

BIOTECH TECH TRANSFER AND TRANSLATING INNOVATION

PREMIUM 3

Tech transfer heads discuss the innovative approaches being taken and the roles TTOs continue to play, and the outcomes they are effecting to support early stage translation.

Moderator: **Iain Thomas**, Head of Life Sciences, Cambridge Enterprise
Paul Ashley, Head of Technology Transfer, Oxford University Innovation
Tony Hickson, Managing Director, Tech Transfer, Imperial Innovations
Pascale Auge, CEO, Inserm Transfert
Viktor Drvota, CEO, Karolinska Development
Isobel Finnie, Partner, Haseltine Lake LLP

GROWTH FINANCE ENVIRONMENT IN BIOTECH

PREMIUM 2

Venture fund executives host an open and frank debate on the continued influence of venture capital on the sector and their appetite for growth and follow-on investment.

Moderator: **Ian Jones**, European Patent Attorney, Gill Jennings & Every
Giovanni Mariggi, Principal, Medixi
Deborah Harland, Partner, SR-One
Dirk Kersten, Managing Director, INKEF Capital
Patrick van Beneden, Partner, GIMV
Vanessa Malier, Managing Partner, Kurma Partners

11.30

COMMERCIAL STRATEGIC INVESTMENT IN MEDTECH

PREMIUM 1

Commercial medtech leaders from large and mid-sized global corporates discuss how they see the industry evolving and what continued role they see for strategic innovation investments.

Moderator: **Erik Milch**, Partner, Cooley
Jonathan Goldstein, Director, Corporate Research and Ventures, Boston Scientific Ventures
Nissim Darvish, Senior Managing Director, Orbimed
Sourabh Pagaria, Senior Vice President and General Manager, Enterprise Services & Solutions, Siemens Healthineers
Assaf Barnea, CEO, Sanara Ventures
Tushar Singhvi, VP, Corporate Development and Investments, Crescent Enterprise-VC

12.15

SEED FUNDING FOR BIOTECH DEVELOPMENT

PREMIUM 3

Executives from a number of prominent seed funds discuss the dynamic that presently exists and what it will take to create an EU seed capital market.

Moderator: **Savvas Neophytou**, Head of Life Sciences, Deepbridge Capital
Piyush Unalkat, Head of Technology Transfer, EIF
Alain Huriez, Chairman and Managing Partner, Advent France Biotechnology
Georgina Murphy, Senior Investment Associate, Atlantic Bridge
Soren Moller, Managing Partner, Novo Seeds
Frank Hensel, Senior Investment Manager, High-Tech Gründerfonds
Edoardo Negroni, Managing Partner, AuroraA-TT

NEW FUNDS ON THE BLOCK

PREMIUM 2

Executives from recently closed new funds discuss their mandates, preferred investment allocations and their sentiment on future sector performance.

Moderator: **John Hodgson**, Data Editor, Pharma, SCRIP Pharma Intelligence
Edward van Wezel, Managing Partner, BioGeneration Ventures
Assaf Barnea, CEO, Sanara Ventures
Ingrid Teigland Akay, Managing Partner, Hadean Ventures

12.15

PAN-EUROPEAN MEDTECH SEED FUNDING

PREMIUM 1

Executives from a number of prominent technology seed funds and venture firms discuss the investment landscape for emerging medtech start-ups.

Moderator: **Elizabeth Cairns**, Medtech Reporter, EP Vantage
Claudio Rumazza, Partner, Innogest
Christoph Ruedig, Partner, Albion Capital
Antonio Sánchez-Cordero, Operating Partner, Accelmed
Martin Pfister, Senior Investment Manager, High-Tech Gründerfonds

1.00

NETWORKING LUNCH, 1-2-1 PARTNERING AND NETWORKING

HOSTED BY



11.30

Inv€stable

PRIVATE DINING

CEOs from the UK and Europe's most progressive **drug discovery, research and development** companies take to the podium to present their company and research to qualified investors and pharma BD&L heads.

Six companies will present for 15mins inc. Q&A.

11.30 Keith Blundy, CEO



11.45 Peter Pack, CEO



12.00 Paul Ko Ferrigno, CEO



12.15 Tim Wilson, CEO



12.30 David Hipkiss, CEO



12.45 Rainer Lichtenberger, CEO



11.30

Inv€stable

SPECIALIST

CEOs from the UK and Europe's most progressive **medtech, diagnostic and medical device** companies take to the podium to present their company and technology to qualified investors and commercial leader BD&L heads.

Six companies will present for 15mins inc. Q&A.

11.30 Andreas Caduff, CEO



11.45 Andrew Shailer-Smith, CEO



12.00 Theresa Deisher, President



12.15 David Horna Tomas, Director



12.30 Paul Vichi, President



12.45 Alex Sheppard, Commercial Director



11.15

biotechandmoney
UK CEO FORUM

UK CEO Forum is a biannual, closed door, Chatham House Rule, invite-only forum for CEOs, CFOs and chairmen of listed and soon-to-be listed **UK**-based life science and healthcare companies.

This forum provides peer-to-peer review and open, honest and frank debate between like-minded executives and a selection of prominent investors.

The forum will provide opportunities for executives to share their successes and debate the opportunities and obstacles that sit between them and their strategic ambitions.

You must be a **CEO FORUM** badge holder to access this forum.

Co-hosts



11.15

biotechandmoney
EUROPEAN CEO FORUM

EU CEO Forum is a biannual, closed door, Chatham House Rule, invite-only forum for CEOs, CFOs and chairmen of listed and soon-to-be listed **France, BEN-ELUX, DACH, Italy and Spain**-based life science and healthcare companies.

This forum provides peer-to-peer review and open, honest and frank debate between like-minded executives and a selection of prominent investors.

The forum will provide opportunities for executives to share their successes and debate the opportunities and obstacles that sit between them and their strategic ambitions.

You must be a **CEO FORUM** badge holder to access this forum.

Host



1.00

NETWORKING LUNCH, 1-2-1 PARTNERING AND NETWORKING

HOSTED BY



2.00

CORPORATE VENTURE AND STRATEGIC INVESTOR PARADIGMS

PREMIUM 3

Executives from the most active corporate venture arms discuss the evolving nature of their role in funding and supporting early and growth stage companies.

Moderator: Lisa Urquhart,

Editor, EP Vantage

Johnston Erwin, VP, Corporate Business Development, Eli Lilly & Co.

Jasper Bos, Vice President, Head of the Healthcare Fund, Merck Ventures

Erica Whittaker, VP, Head of UCB Ventures, UCB Pharma

Beverley Carr, VP, Business Development, Immunoinflammation Therapy Area, GSK

IN CONVERSATION WITH... BUILDING BIOTECH COMPANIES WITH SCALE

PREMIUM 2

Executives from life science companies that have successfully built and scaled their businesses share their war stories, KSFs and the strategies companies should pursue in the quest for growth.

Moderator: John Hodgson, Data Editor, Pharma, SCRIP Pharma Intelligence

Onno Van de Stolpe, CEO, Galapagos

Darrin Disley, CEO, Horizon Discovery Group

Edwin Moses, CEO, Ablynx

Rodger Novak, CEO, CRISPR Therapeutics

2.00

MEDTECH VENTURE INVESTMENT

PREMIUM 1

Executives from active venture capital funds in medtech to discuss the range of sources of funding and investment open to medtech and medical device companies, how they see medtech investment developing in the year ahead and what is critical to the evolution of the sector to build billion dollar companies.

Moderator: Madeleine

Armstrong, Reporter, EP Vantage

Joachim Rautter, Managing Director, Peppermint Venture Partners

Daniel O'Mahony, Partner, Seroba Life Sciences

Thom Rasche, Partner, EARLYBIRD Venture Capital

Janke Dittmer, Partner, Gilde Healthcare

Christoph Kausch, Founding Partner and CEO, MTIP MedTech Innovation Partners

2.45

EARLY STAGE PHARMA COLLABORATION

PREMIUM 3

Executives from early-stage pharma innovation teams discuss and debate the evolving dynamic and role that pharma play in early stage collaborations and how sector interactions are changing.

Moderator: Jennifer

Smith-Parker, Editor, EMEA GlobalData

Tim Luker, Senior Director, Emerging Technology & Innovation, Business Development, Eli Lilly & Co.

Maria Dahl, Executive Director, Business Development, Oncology, AstraZeneca

Pavithra Sundareshan, Senior Director, New Ventures and Transaction Lead, J&J Innovation

Phil L'Huillier, Head, European Innovation Hub, MSD

Nick Clarke, Head of UK Academic Partnerships, Pfizer

EIB QUASI EQUITY INVESTMENTS

PREMIUM 2

The Investment Plan for Europe continues to support innovative projects in the health sector. Executives receiving equity-type investment under EFSI and InnovFin discuss the overarching aim of these schemes and share their approaches to benefiting from this innovative financing model.

Moderator: Louise Fordham, Editor, Biotech and Money

Henri-François Boedt, Senior Loan Officer, Growth Capital and Innovation Finance, European Investment Bank

Peter Llewellyn-Davies, CFO and CBO, APEIRON Biologics

Florence Sejourne, CEO, Da Volterra

2.45

FUNDING AR, AI & VR START-UPS TO GROWTH

PREMIUM 1

With the advances in technology, VR, AR and artificial intelligence (AI) will create entirely new applications in healthcare.

This session will look at how to build out the ecosystem of AR, VR and AI tech in the healthcare industry and what investors and start-ups need to do to help move the industry from analogue to digital through new technology.

Moderator: Jennifer

Kite-Powell, Technology Contributor, Forbes.com

James Shaw, Co-Founder, JAG Shaw Baker

Isabel van de Keere, CEO, Immersive Rehab

Tommi Lehtonen, CEO, Blueprint Genetics

Andrew Chapman, Digital Health, Sector Lead, Digital Catapult

3.30

AFTERNOON REFRESHMENTS, 1-2-1 PARTNERING AND NETWORKING

2.00

PRIVATE DINING

Inv€stable

CEOs from the UK and Europe's most progressive **drug discovery, research and development** companies take to the podium to present their company and research to qualified investors and pharma BD&L heads.

Six companies will present for 15mins inc. Q&A.

2.00 **Fred Jacobs**, CEO



2.15 **Niall Martin**, CEO



2.30 **Randolph Hubbell**, CEO



2.45 **Thomas Lienard**, CEO



3.00 **Martin Ostermaier**, CEO



3.15 **Raul Insa**, CEO



2.00

SPECIALIST

Inv€stable

CEOs from the UK and Europe's most progressive **medtech, diagnostic and medical device** companies take to the podium to present their company and technology to qualified investors and commercial leader BD&L heads.

Six companies will present for 15mins inc. Q&A.

2.00 **Will Dracup**, CEO



2.15 **Andrew Holman**, CEO



2.30 **Friedrich Jacobi**, CFO



2.45 **Cameron Reynolds**, CEO



3.00 **Andrew Tasker**, CEO



3.15 **Marcin Halicki**, CEO



1.45

CREATIVE 2



Nordic CEO Forum is a biannual, closed door, Chatham House Rule, invite-only forum for CEOs, CFOs and chairmen of listed and soon-to-be listed **Nordic**-based life science and healthcare companies.

This forum provides peer-to-peer review and open, honest and frank debate between like-minded executives and a selection of prominent investors.

The forum will provide opportunities for executives to share their successes and debate the opportunities and obstacles that sit between them and their strategic ambitions.

You must be a **CEO FORUM** badge holder to access this forum.

Co-hosts



3.30

AFTERNOON REFRESHMENTS, 1-2-1 PARTNERING AND NETWORKING

4.00

THERAPEUTIC
ROUNDTABLE

Immuno-Oncology

Anna Williamson, Oncology
Business Development,
Genentech Partnering

- Where are the opportunities to work with Genentech?
- What are their external R&D approaches and their corporate development partnering strategies?
- What are they looking for?

This is a **pre-registered** session but space may be available on the day.

PREMIUM 2

4.00

THERAPEUTIC
ROUNDTABLE

Neuroscience / CNS

Jennifer Laird, Senior Director,
Neuroscience S&E, Eli Lilly &
Co.

- Where are the opportunities to work with Eli Lilly?
- What are their external R&D approaches and their corporate development partnering strategies?
- What are they looking for?

This is a **pre-registered** session but space may be available on the day.

PREMIUM 3

4.00

MEDTECH SHARK TANK

Five companies will present to the Sharks and audience, to secure a deal that could change the fortunes of their business.

Panellists:

Christopher Cleary, VP
Corporate Development,
Medtronic
Dennis Crowley, SVP, Business
Development & Licensing,
Baxter
Daniel O'Mahony, Partner,
Seroba Life Sciences

4.00 **Israel Birenbaum**, CEO



4.15 **Simon Hubbert**,
Management Consultant

HAEMAIR

4.30 **Reimar Schlingensiepen**,
Head BD and Strategy



4.45 **Harry Rowland**, CEO



4.00

biotechandmoney
IP WORKSHOP

IP strategies for success. Protecting and managing your intellectual property (IP) and being aware of all the associated risks is vital and can mean the difference between success or failure.

Whether you are preparing your patent portfolio for due diligence, seeking investment, looking to license or assign a technology and its supporting IP, growing or extending protection for a new innovation, addressing freedom to operate or overcoming third party IP, there are key considerations that should inform a successful IP strategy.

You must be **pre-registered** to attend this 12-person workshop.

Host:

HASELTINE LAKE LLP
EUROPEAN PATENT AND TRADE MARK ATTORNEYS

Isobel Finnie,
Partner, Haseltine
Lake LLP

5.10

IN CONVERSATION WITH...
THE INTERSECTION OF DATA-DRIVEN PRODUCTS AND HEALTHCARE

In 2017 McLaren Applied Technologies, the advanced technology, innovation and design company, and Deloitte, announced the launch of a new partnership to pave the way to build data-driven business products. Initially focused on healthcare, life sciences, retail and transport, the partnership looks to bridge the 'physical-to-digital' divide by helping organisations make sense of data.

In this 'In conversation with...' fireside chat, the CMO of MAT will discuss his vision for using advanced analytics, AI and machine learning across key industries and in particular what this means for delivering information in an automated and more effective way.

Interviewer: Summer Park, Business Development Director, PharmaVentures
Adam Hill, Chief Medical Officer, McLaren Applied Technologies

PREMIUM 2

5.30

NETWORKING DRINKS RECEPTION

(INVESTOR DINNER WILL FOLLOW AT 7PM)



4.00

Inv€stable

PRIVATE DINING

CEOs from the UK and Europe's most progressive **drug discovery, research and development** companies take to the podium to present their company and research to qualified investors and pharma BD&L heads.

4.00 Pekka Simula, CEO



4.15 Michael Stein, CEO



4.30 Carlos de Sousa, CEO



4.45 Joern Aldag, CEO



5.00 Lars Hedby, CEO



4.00

Inv€stable

SPECIALIST

CEOs from the UK and Europe's most progressive **drug discovery, research and development, medtech and device** companies take to the podium to present their company and research to qualified investors, pharma and commercial leader BD&L heads.

4.00 Celina-Lea Halioua Haubold, BD



4.15 Christine Lind, CEO



4.30 Hicham Youssoufi Alaoui, CEO



4.45 Jeremy Russell, CEO



4.55 Robert Milnes, CEO



5.05 Kevin Kelleher, CEO



5.15 Idalia Dawidowska, CEO



4.00

Biotech and Money is teaming up with some of the world's foremost experts, advisers, bankers and consultants to help CEOs and CFOs navigate the how, what, where and when of successful cross-border M&A.

The key USPs are the very high level and calibre of attendee and programme, exclusivity, and the personalised approach.

In addition to 'no holds barred' discussions, it will feature tailored sessions, where each registering company will receive individual attention from the experts to talk through strategy, tactics, mechanics and ideas unique to them.

- Keynote address: The current state of the deal environment
- Anatomy of an M&A: Back-to-back case study discussions of M&As
- Determining and defining your M&A strategy: before and during the deal
- Managing risks in cross-border transactions
- After the deal: the importance of effective integration
- Financial PR and communications
- Banks, advisors, and investors
- Regulatory requirements and M&A checklists

You must be **pre-registered** to attend this workshop.

Host:

ALLEN & OVERY

5.30

NETWORKING DRINKS RECEPTION
(INVESTOR DINNER WILL FOLLOW AT 7PM)



COMPANY ANNOUNCEMENT

biotechandmoney
bringing deals to life



Connect
with
purpose

Dear colleague,

After nearly four years as Biotech and Money, we felt it was time for a change, and where better to announce it than at this year's congress.

We felt that whilst Biotech and Money was perfectly aligned with what we've focused on to date, it's not truly reflective of where we are heading, and the value that we will be offering our customers and partners in the future.

We have become more than just biotech, more than just money.

But worry not, you will still be able to rely on **LSX** to deliver to the same high standards that you've become accustomed to. It just means we will be broadening out our offering to our life science executive community, which can only be a good thing.

In the coming weeks we'll be transitioning to the new brand, company name and website, so be sure to keep an eye out for further announcements and communications, but as a valued customer, we wanted you to be the first to know.

Warm Regards

Neil Darkes Terry O'Dwyer
Co-CEO Co-CEO



DAY 2 - TUESDAY 6TH FEBRUARY 2018

REGISTRATION, BREAKFAST AND 1-2-1 PARTNERING

8.30

WELCOME REMARKS

Neil Darkes, Co-CEO, Biotech and Money

9.55

IN CONVERSATION WITH...
PHARMA AND BIOTECH MEGA DEALS

An executive from a life science company that has been involved in one of the industry's biggest deals / transactions in recent times share war stories, KSFs and visions for their burgeoning businesses.

This session contains an 'In conversation with...' moderated fireside chat.

Moderator: Jacob Plieth, Senior Reporter, EP Vantage

Rigontec and MSD:
Christian Schetter, CEO, Rigontec

10.00

PREMIUM 2 & 3

10.20

PHARMA CORPORATE AND BUSINESS DEVELOPMENT

Global / regional heads from some of the industry's leading large biotech / pharma companies discuss hot areas of M&A activity, what strategies will create winners and losers, and how companies can create optimal opportunities in the year ahead.

Moderator: Ben Thorpe, Head of EMEA Healthcare Investment Banking, Goldman Sachs
Subesh Williams, SVP, Global Corporate Development, GSK
Angus Grant, CVP, Business Development, Celgene
Miguel Stevens, VP, Head of Global BD, UCB
Guillaume Vignon, VP, Head of Oncology Licensing & Business Development, EMD Serono

PREMIUM 2 & 3

11.00

MORNING REFRESHMENTS, 1-2-1 PARTNERING AND NETWORKING

WELCOME REMARKS

Taz Shariff, SVP, Biotech and Money

9.55

IN CONVERSATION WITH...
MEDTECH MEGA DEALS

An executive from a medtech company that has been involved in one of the industry's largest deals / transactions in recent times share war stories, KSFs and opinions on the current deal making environment.

This session contains an 'In conversation with...' moderated fireside chat.

Moderator: Madeleine Armstrong, Reporter, EP Vantage

Medtronic and Covidien:
Christopher Cleary, VP Corporate Development, Medtronic

10.00

PREMIUM 1

10.20

COMMERCIAL LEADER BD, M&A AND TRANSACTIONS

Global / regional heads from some of the industry's commercial leaders discuss hot areas of M&A and partnering activity, what strategies will create winners and losers and how industry can develop strategies for reducing coverage and commercialisation risk.

Moderator: Summer Park, Business Development Director, PharmaVentures
Christopher Cleary, VP Corporate Development, Medtronic
Pierre Chauvineau, VP, Rhythm Management, Boston Scientific
Dennis Crowley, SVP, Business Development & Licensing, Baxter

PREMIUM 1

11.30

PREMIUM 2&3

ANATOMY OF A...PRIVATE FINANCE RAISE

Executives from some of the industry's leading therapeutic biotechs that have recently concluded significant private finance raises share their war stories, KSFs and opinions on current venture fund appetite.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Joe Pillman, Strategic Consultant, JAG Shaw Baker

Jean-Philippe Combal, CEO, Vivet Therapeutics

Marc Lemonnier, CEO, Antabio

Timm Jessen, CEO, Topas Therapeutics

11.30

PREMIUM 1

ANATOMY OF A...PRIVATE FINANCE RAISE

Executives from some of the industry's leading medtech / device companies that have recently concluded significant private finance raises share their war stories, KSFs and opinions on current venture fund appetite.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Tina Tan, Editor-in-Chief, Medtech Insight

Martin Frost, CEO, Cambridge Medical Robotics

Tommi Lehtonen, CEO, Blueprint Genetics

Steve Atkinson, CEO, Atlantic Therapeutics

Rob de Ree, Operating Partner, BioGeneration Ventures and Supervisory Board Member, Mellon Medical

12.15

PREMIUM 2&3

ANATOMY OF A...HYBRID BUSINESS MODEL

We invite executives from some of the industry's leading life science companies that have successfully married proprietary development programmes with a service offering. Executives will share their war stories and the KSFs to progressing their revenue generation models.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Sophie McGrath, Partner, Brown Rudnick

Darrin Disley, CEO, Horizon Discovery Group

Pawel Przewiezlikowski, CEO, Selvita

Shaun Chilton, Group CEO, Clinigen Group

12.15

PREMIUM 1

ANATOMY OF A...MEDTECH IPO

We invite executives from some of the industry's leading medtech companies that have concluded successful public listings will share their war stories, KSFs and ways to navigate the public markets.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Adam Kostyál, SVP and Head of European Listings, Nasdaq

Richard Davies, CEO, Bone Support

Lena Soderstrom, CEO, Senzime

1.00

NETWORKING LUNCH, 1-2-1 PARTNERING AND NETWORKING

11.30

Inv€stable

PRIVATE DINING

CEOs from the UK and Europe's most progressive **drug discovery, research and development** companies take to the podium to present their company and research to qualified investors and pharma BD&L heads.

11.30 **Luc Dochez**, CEO



11.45 **Gregory Mario**, CEO



12.00 **Mariola Soehngen**, CEO



12.15 **Ulla Buhl Jensen**, COO



12.30 **Nette Buitelaar**, CBO



12.45 **Paul Plested**, CEO



11.30

Inv€stable

SPECIALIST

CEOs from the UK and Europe's most progressive **drug discovery, research and development**, companies take to the podium to present their company and research to qualified investors pharma and BD&L heads.

11.30 **John Prendergast**, Lead Director



11.45 **Ulf Wiinberg**, Acting CEO



12.00 **Emma Sceats**, CEO



12.15 **Jasper van Weerd**, CEO



12.30 **Therese Kinsella**, CEO



12.45 **Simon Kerr**, CEO



1.00

NETWORKING LUNCH, 1-2-1 PARTNERING AND NETWORKING

2.00

PREMIUM 2 & 3

ANATOMY OF A...BIOTECH LICENSING DEAL

Executives from some of the industry's leading life science companies that have recently conducted successful, high profile deals share their war stories, KSFs and opinions on the deal making environment.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: **Summer Park**, Business Development Director, PharmaVentures
Sarah Howell, CEO, Arecor
Gita Dittmar, Head of Corporate Development, Ethris
Ajan Reginald, CEO, Celixir

ANATOMY OF A...BIOTECH IPO

We invite executives from some of the industry's leading life science companies that have concluded successful public listings to share their war stories, KSFs and ways to navigate the public markets.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: **Philip Broke**, Partner, White & Case
Neil Clark, CEO, Destiny Pharma
Niels Riedemann, CEO, InflaRx

2.00

PREMIUM 1

ANATOMY OF A...HI-GROWTH / DEAL MAKING MEDTECH / DEVICE COMPANY

We invite medtech / device company executives that are challenging the status-quo and successfully developing strategies to evolve their business. Executives will share their war stories and the KSFs to progressing their revenue generation models, deal making and co-development opportunities.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: **Robert Darwin**, Partner, Hogan Lovells
James Greene, CEO, Medlumics
Simon Hubbert, Executive Chairman, LIG-Biowise
Elisa Petris, Partner, Syncona Ltd

3.30

PREMIUM 2 & 3

CLOSING PANEL: TRACKING THE INDUSTRY TRENDS

Pricing pressures, regulatory changes, emerging innovations, patient-centric models and growth opportunities remain for life sciences companies in 2018. What are the trends impacting life sciences companies in the coming year and how should companies and executives respond to the pressures and position themselves for success?

Moderator: **Andy Smith**, Director-Analyst, Healthcare, Edison
Jens Lindqvist, Partner and Senior Research Analyst, Life Sciences, N+1 Singer
Tara Raveendran, Head of Life Sciences Research, Shore Capital
Julie Simmonds, Director, Equity Research, Panmure Gordon
Max Herrmann, Managing Director, Stifel
Mick Cooper, Healthcare and Life Sciences Analyst, Trinity Delta

CLOSE OF CONFERENCE

4.10

ANCILLARY BOOTCAMPS

10.00

FTI CONSULTING OFFICE



US IPO BOOTCAMP 10AM - 5.00PM, 6TH FEBRUARY

Biotech and Money is teaming up with some of the world's foremost experts, advisers, bankers and consultants to help CEOs and CFOs navigate the how, what, where and when of a successful **US IPO**.

The Bootcamp will provide opportunities for 9 highly qualified European life science corporate CEOs to come together for a 1-day bootcamp on the how, where and when of a **Nasdaq / US IPO**.

All attendees will need to meet a strict vetting procedure to qualify.

The day will consist of a capital market presentation, case study led roundtable discussion followed by 1-on-1 consultative meetings with 1 investment bank, 1 law firm, 1 global advisory firm, 1 executive search firm, 1 IR firm, 1 global exchange and 1 American depository bank.

You must be **pre-registered** to attend this day.

Offices of FTI Consulting
200 Aldersgate Street, London, EC1A 4HD

Co-hosts:



COVINGTON



9.00

N+1 SINGER OFFICE



UK IPO BOOTCAMP 9AM - 4.00PM, 7TH FEBRUARY

Biotech and Money is teaming up with some of the world's foremost experts, advisers, bankers and consultants to help CEOs and CFOs navigate the how, what, where and when of a successful **UK IPO**.

The Bootcamp will provide opportunities for 8 highly qualified European life science corporate CEOs to come together for a 1-day bootcamp on the how, where and when of a **UK IPO**.

All attendees will need to meet a strict vetting procedure to qualify.

The day will consist of a capital market presentation, case study led roundtable discussion followed by 1-on-1 consultative meetings with 1 investment bank, 1 law firm, 1 global advisory firm, 1 executive search and 1 IR firm.

You must be **pre-registered** to attend this day.

Offices of N+1 Singer
1 Bartholomew Lane, London, EC2N 2AX

Co-hosts:

ALLEN & OVERY



N+1 SINGER



Investable

**YOUR ON-SITE GUIDE TO THE 50+
SHOWCASES TAKING PLACE DURING
THE 2-DAY CONGRESS**

BIOTECH - BLUE | MEDTECH - GREEN



Presenter: Emma Sceats, CEO
Track: Biotech
Time / Date: 12.00, Day 2, 6th February
Room: Specialist
Target Market: Dermatology, immunology, infectious disease, oncology
Description: A drug discovery company enabled by a unique and proven human Organ-on-a-Chip platform, LiverChip® of parent company CN Bio Innovations.

Stage: Growth
Ownership: Private
Country: UK



Presenter: David Horna Tomas, Director
Track: Medtech
Time / Date: 12.15, Day 1, 5th February
Room: Specialist
Target Market: Cell and gene therapy
Description: At Aglaris we envision a world in which personalised medicine, regenerative medicine and cell therapies are the tools that propel the field of general medicine towards achieving new goals like finding the cure for illnesses which, to date, have been incurable.
Stage: Early growth
Ownership: Private
Country: UK



Presenter: Niall Martin, CEO
Track: Biotech
Time / Date: 2.15, Day 1, 5th February
Room: Private Dining
Target Market: Oncology
Description: We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells.
Stage: Early growth
Ownership: Private
Country: UK



Presenter: Andrew Shailer-Smith, CEO
Track: Medtech
Time / Date: 11.45, Day 1, 5th February
Room: Specialist
Target Market: Cell and gene therapy
Description: Astraveus is a Paris-based medtech dedicated to building high tech equipment to manufacture autologous cell and gene therapies (CGT).

Stage: Early growth
Ownership: Private
Country: France



Presenter: Rainer Lichtenberger, CEO
Track: Biotech
Time / Date: 12.45, Day 1, 5th February
Room: Private Dining
Target Market: Infectious disease, dermatology
Description: A company based on patented research for the benefit of MEK inhibitors in the treatment of viral and bacterial infections.

Stage: Early growth
Ownership: Private
Country: Germany



Presenter: Therese Kinsella, CEO
Track: Biotech
Time / Date: 12.30, Day 2, 6th February
Room: Specialist
Target Market: Cardiovascular, pulmonology
Description: Novel therapeutics for Pulmonary Arterial Hypertension.

Stage: Early growth
Ownership: Private
Country: Ireland



Presenter: Theresa Deisher, CEO
Track: Medtech
Time / Date: 12.00, Day 1, 5th February
Room: Specialist
Target Market: Regen med, oncology
Description: Developed patented, breakthrough cell therapy-focused technologies to ensure an up to 30 fold increase in the delivery of these therapies to their intended medical target – with a focus on regenerative medicine and cancer therapies.
Stage: Early growth
Ownership: Private
Country: USA



Presenter: Nette Buitelaar, CBO
Track: Biotech
Time / Date: 12.30, Day 2, 6th February
Room: Private Dining
Target Market: Biosimilars, mAbs, bone
Description: Biosana Pharma is deploying two platforms and generating a mAb pipeline with these technologies. With these platforms we generate a pipeline of biosimilars and biobetters.
Stage: Early growth
Ownership: Private
Country: The Netherlands



Presenter: Israel Birenbaum, CEO
Track: Medtech Shark Tank
Time / Date: 4.00, Day 1, 5th February
Room: Premium 1
Target Market: Oncology, urology, surgical
Description: A biodegradable balloon spacer platform, suitable for diverse unmet clinical needs. Current focus is the radiotherapy spacers market, intended to protect healthy tissue from radiation during oncology treatments.
Stage: Early growth
Ownership: Private
Country: Israel



Presenter: Hicham Youssoufi Alaoui, CEO
Track: Biotech
Time / Date: 4.30, Day 1, 5th February
Room: Specialist
Target Market: Orthopaedics
Description: A leader in cartilage treatments. BioTissue treatments for cartilage regeneration are biocompatible, tissue-conserving and completely absorbable. The implant develops in the cartilage defect and integrates into the surrounding environment.
Stage: Early growth
Ownership: Private
Country: Switzerland



Presenter: Andreas Caduff, CEO
Track: Medtech
Time / Date: 11.30, Day 1, 5th February
Room: Specialist
Target Market: Digital health
Description: Biovotion is an award-winning wearable physiology monitoring company and provides integrated solutions with connected hardware, value-added data analytics and services.
Stage: Early growth
Ownership: Private
Country: Switzerland



Presenter: Will Dracup, CEO
Track: Medtech
Time / Date: 2.00, Day 1, 5th February
Room: Specialist
Target Market: IV diagnostics, oncology
Description: Biosignatures are developing the next generation proteomic based cancer diagnostics. Creating blood tests for detection of prostate, bladder & renal cancer.
Stage: Seed / early growth
Ownership: Private
Country: UK



Presenter: Thomas Lienard, CEO
Track: Biotech
Time / Date: 2.45, Day 1, 5th February
Room: Private Dining
Target Market: Orthopaedics
Description: A bone cell therapy company specializing in addressing unmet medical needs in the field of bone fracture repair and bone fracture prevention. Bone Therapeutics develops both autologous and allogeneic innovative cell therapy products.
Stage: Growth
Ownership: Private
Country: Belgium



Presenter: Marcin Halicki, CEO
Track: Medtech
Time / Date: 3.15, Day 1, 5th February
Room: Specialist
Target Market: Oncology, digital health
Description: Developed a state-of-the-art technology called a "contact thermography". Braster is the only company that has developed a method of manufacturing liquid crystal matrices used for breast cancer diagnostics.
Stage: Growth
Ownership: Public (Warsaw Stock Exchange)
Country: Poland



Presenter: Randolph Hubbell, CEO
Track: Biotech
Time / Date: 2.30, Day 1, 5th February
Room: Private Dining
Target Market: Bone, orthopaedics, regenerative medicine
Description: A clinical development stage start-up with two product candidates in development. Candidate #1, Bone Healing Accelerant, is phase III ready and the second product candidate, Tissue Healing Accelerant, is phase II ready.
Stage: Growth
Ownership: Private
Country: USA



Presenter: Peter Pack, CEO
Track: Biotech
Time / Date: 11.45, Day 1, 5th February
Room: Private Dining
Target Market: Immunology, oncology
Description: A biopharmaceutical company that is using its patent-protected transgenic mouse platform to efficiently discover and develop potent, highly differentiated multi-functional Humabody® therapeutics with a focus on oncology.
Stage: Growth
Ownership: Private
Country: UK



Presenter: Simon Kerr, CEO
Track: Biotech
Time / Date: 12.45, Day 2, 6th February
Room: Specialist
Target Market: CNS, gastroenterology, inflammation, nephrology, neurology, oncology
Description: Emerging biopharma company focused on the discovery & development of novel cyclophilin inhibitors to treat a range of acute and chronic degenerative diseases.

Stage: Early growth
Ownership: Private
Country: UK



Presenter: Harry Rowlands, CEO
Track: Medtech SharkTank
Time / Date: 4.45, Day 1, 5th February
Room: Premium 1
Target Market: CV, digital health (medtech)
Description: Endotronix is developing hemodynamic monitoring solutions to help detect worsening heart failure earlier than ever before.

Stage: Early growth
Ownership: Private
Country: USA



Presenter: David Hipkiss, CEO
Track: Biotech
Time / Date: 12.30, Day 1, 5th February
Room: Private Dining
Target Market: Vaccines
Description: Enesi Pharma is an early stage pharmaceutical company developing a range of unique, injectable solid dose, drug-device combination products, with a primary focus on vaccines.

Stage: Early growth
Ownership: Private
Country: UK



Presenter: Andrew Tasker, CEO
Track: Medtech
Time / Date: 3.00, Day 1, 5th February
Room: Specialist
Target Market: Urology, female health

Description: Pelviva® is a life-changing technological breakthrough for the treatment of weak pelvic floor muscles that cause bladder leaks in women.

Stage: Growth, late growth stage
Ownership: Private
Country: UK



Presenter: Friedrich Jacobi, CFO
Track: Medtech
Time / Date: 2.30, Day 1, 5th February
Room: ENT, neurology, surgical instruments
Target Market: Urology, female health
Description: Fiagon is a leading supplier of navigated surgical instruments for ENT, Brain and Spine applications. The smart navigation technology improves patient safety, reduces failure rate and lowers overall procedure cost.

Stage: Growth
Ownership: Private
Country: Germany



Presenter: Simon Hubbert, Management Consultant
Track: Medtech Shark Tank
Time / Date: 4.15, Day 1, 5th February
Room: Premium 1
Target Market: Respiratory, surgical
Description: Haemair will provide support for patients with both acute and chronic respiratory disease and support less well patients selected for minimally invasive cardiac procedures.
Stage: Growth, late growth stage
Ownership: Private
Country: UK



Presenter: Ulf Wiinberg, Acting CEO
Track: Biotech
Date / Time: 11.45, Day 2, 6th February
Room: Specialist
Target Market: CNS, immunology, inflammation, nephrology, neurology, rheumatology, transplantation
Description: Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases.
Stage: Growth
Ownership: Public (NASDAQ Stockholm)
Country: Sweden



Presenter: John Prendergast, Lead Director
Track: Biotech
Date / Time: 11.30, Day 2, 6th February
Room: Specialist
Target Market: Immunology, infectious disease, oncology, vaccines
Description: Focused on the field of cancer immunotherapy. This company's cancer vaccine is called ImPACT, short for Immune Pan-Antigen Cytotoxic Therapy.

Stage: Early growth
Ownership: Public (NASDAQ)
Country: USA

Presenter: Pekka Simula, CEO
Track: Biotech
Time / Date: 4.00, Day 1, 5th February
Room: Private Dining
Target Market: Cardiovascular, CNS, oncology, lymphedema
Description: Regenerative medicine for unmet clinical needs. CDNF for disease modification in neurodegenerative diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer associated lymphedema.
Stage: Early growth
Ownership: Public (NASDAQ First North)
Country: Finland

Presenter: Joern Aldag, CEO
Track: Biotech
Time / Date: 4.45, Day 1, 5th February
Room: Private Dining
Target Market: Infectious disease, oncology
Description: Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology.
Stage: Growth
Ownership: Private
Country: Austria

Presenter: Lars Hedby, CEO
Track: Biotech
Time / Date: 5.00, Day 1, 5th February
Room: Private Dining
Target Market: Haematology, immunology, nephrology
Description: Idogen develops cell therapies with the goal of inducing long-lasting immune tolerance. Idogen's technology is based on a unique and patented method of inducing tolerogenic dendritic cells.
Stage: Early growth
Ownership: Public (AktieTarget)
Country: Sweden

Presenter: Tim Wilson, CEO
Track: Biotech
Time / Date: 12.15, Day 1, 5th February
Room: Private Dining
Target Market: Oncology
Description: IGEN is a UK-based Immuno-Oncology company focused on the development of IgE antibody drugs to fight cancer.
Stage: Early growth
Ownership: Private
Country: UK

Presenter: Carlos de Sousa, CEO
Track: Biotech
Time / Date: 4.30, Day 1, 5th February
Room: Private Dining
Target Market: Oncology
Description: Immunicum is developing novel immuno-oncology therapies against a range of solid tumors. The approach is based on allogeneic dendritic cells that are designed to stimulate a personalized anti-tumor immune response in each patient.
Stage: Early growth
Ownership: Public (NASDAQ Stockholm)
Country: Sweden

Presenter: Andrew Holman, CEO
Track: Medtech
Time / Date: 2.15, Day 1, 5th February
Room: Specialist
Target Market: Immunology, inflammation, rheumatology
Description: Inmedix has discovered & is commercializing a novel class of diagnostics & therapeutics. Our approach focuses on autonomic nervous system (ANS) control of stress responses within the brain.
Stage: Seed
Ownership: Private
Country: USA

Presenter: Martin Ostermaier, CEO
Track: Biotech
Time / Date: 3.00, Day 1, 5th February
Room: Private Dining
Target Market: CV, oncology, pulmonology, respiratory
Description: The InterAx drug discovery platform efficiently delivers novel lead compounds that are hallmarked by confined cellular signaling profiles.
Stage: Early growth
Ownership: Private
Country: Switzerland

Presenter: Alex Sheppard, Commercial Director
Track: Medtech
Time / Date: 12.45, Day 1, 5th February
Room: Specialist
Target Market: Infectious disease, IV diagnostics, respiratory
Description: Rapid point of care diagnostics for anti-microbial resistance.
Stage: Early growth
Ownership: Private
Country: UK

Presenter: Jasper van Weerd, CEO
Track: Medtech
Time / Date: 12.15, Day 2, 6th February
Room: Specialist
Target Market: CV, Ophthalmology, orthopaedics, urology
Description: A spin-off of the famous MESA+ Nanotechnology Institute of the University of Twente (NL) with the aim to improve performance, comfort & safety of medical devices powered by our novel coatings.
Stage: Seed / early growth
Ownership: Private
Country: Netherlands

Presenter: Paul Pledsted, CEO
Track: Biotech
Time / Date: 12.45, Day 2, 6th February
Room: Private Dining
Target Market: CV, dermatology, diabetes
Description: A biotech company with a mission to develop and market novel approaches to accelerate wound healing. Our lead product is a gene-delivering cardiac stent, and a topical cream to accelerate wound healing.
Stage: Early growth
Ownership: Private
Country: USA

Presenter: Christine Lind, CEO
Track: Biotech
Time / Date: 4.15, Day 1, 5th February
Room: Specialist
Target Market: Oncology, rheumatology
Description: The discovery and development of transformative cancer drugs. To do this efficiently and with a high success rate we rely on our scientific knowledge, balanced project portfolio, collaborative culture and extensive industry experience.
Stage: Growth
Ownership: Public (NASDAQ OMX)
Country: Sweden

Presenter: Paul Ko Ferrigno, CEO
Track: Biotech
Time / Date: 12.00, Day 1, 5th February
Room: Private Dining
Target Market: Infectious disease
Description: Our proprietary platform technology allows us to efficiently identify new drug targets, validate mechanism and spectrum of action and de-risk the target- all before initiating chemistry.
Stage: Seed, early growth
Ownership: Private
Country: UK

MOLOGEN AG

THE POWER OF IMMUNOTHERAPIES

Presenter: Mariloe Soehngen, CEO
Track: Biotech
Time / Date: 12.00, Day 2, 6th February
Room: Private Dining
Target Market: Infectious disease, oncology
Description: Considered a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.
Stage: Growth
Ownership: Public (Deutsche Börse Xetra)
Country: Germany

OISÍN™

BIOTECHNOLOGIES

Presenter: Celine-Lea Halioua-Haubold, BD
Track: Biotech
Time / Date: 4.00, Day 1, 5th February
Room: Specialist
Target Market: Oncology, senescence
Description: Oisín Biotechnologies' ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself. We invite you to see how.
Stage: Early growth
Ownership: Private
Country: USA

OncoGenesis

Presenter: Paul Vichi, President
Track: Medtech
Time / Date: 12.30, Day 1, 5th February
Room: Specialist
Target Market: IV diagnostics, oncology
Description: Protein-based disease and cancer screening at the POC. Advanced development and testing of a low cost test that will provide access to screening, significantly improving early detection over the current Pap and adjunctive HPV tests.
Stage: Late growth
Ownership: Private
Country: USA

Oncology Venture

Presenter: Ulla Buhl Jensen, COO
Track: Biotech
Time / Date: 12.15, Day 2, 6th February
Room: Private Dining
Target Market: Oncology, immunology
Description: Oncology Venture is a drug development company with a clinical pipeline of six promising Phase2/3 targeted and immuno-oncology assets.
Stage: Growth, late growth
Ownership: Public (AktieTorget)
Country: Denmark

orp

Presenter: Jeremy Russell, CEO
Track: Medtech
Time / Date: 4.45, Day 1, 5th February
Room: Specialist
Target Market: Surgical instruments
Description: We design and manufacture cost-effective robotic systems that hold and manipulate a camera during laparoscopic surgical procedures.
Stage: Early growth
Ownership: Private
Country: UK

OSTOFORM

NOVEL OSTOMY CARE PRODUCTS

Presenter: Kevin Kelleher, CEO
Track: Medtech
Time / Date: 5.05, Day 1, 5th February
Room: Specialist
Target Market: Gastroenterology, dermatology, urology
Description: Ostoform is medical device that aims to manage peristomal skin complications for people with ileostomies.
Stage: Seed
Ownership: Private
Country: Ireland

OvuSense™

Realtime Fertility Monitor

Presenter: Robert Milnes, CEO
Track: Medtech
Time / Date: 4.55, Day 1, 5th February
Room: Specialist
Target Market: Digital health
Description: A clinically proven Fertility and Ovulation Monitor that uses your unique data to give you an 8-day fertile window with 24 hours advanced prediction of ovulation.
Stage: Early growth
Ownership: Private
Country: UK

OXSTEM

Presenter: Michael Stein, CEO
Track: Biotech
Time / Date: 4.15, Day 1, 5th February
Room: Private Dining
Target Market: CV, CNS, dermatology, diabetes, immunology, inflammation, neurology, oncology, ophthalmology
Description: Medical therapeutics for age-related conditions, such as Dementia, Heart Failure, Age-Related Macular Degeneration, Oncology and Diabetes.
Stage: Early growth
Ownership: Private
Country: UK

PENTRACOR

Presenter: Reimar Schlingensiepen, Head BD and Strategy
Track: Medtech Shark Tank
Time / Date: 4.30, Day 1, 5th February
Room: Premium 1
Target Market: CV, CNS, inflammation, rheumatology
Description: Pentracor GmbH produces and markets CRP-adsorbers for extracorporeal therapeutic lowering of C-reactive protein.
Stage: Early growth
Ownership: Private
Country: Germany

RENEPHRA

Presenter: Idalia Dawidowska, CEO
Track: Medtech
Time / Date: 5.15, Day 1, 5th February
Room: Specialist
Target Market: CV, nephrology
Description: Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal in vascular, oncology and other disease areas.
Stage: Seed
Ownership: Private
Country: UK

SOM

BIOTECH
The Drug Repurposing Company

Presenter: Raul Insa, CEO
Track: Biotech
Time / Date: 3.15, Day 1, 5th February
Room: Private Dining
Target Market: CNS, neurology, orphan
Description: SOM Biotech is a global leader in the field of Repurposing drugs for Orphan Indications. We have a strong pipeline of products focused on CNS at preclinical and clinical stages.
Stage: Growth
Ownership: Private
Country: Spain

STORM

THERAPEUTICS

Presenter: Keith Blundy, CEO
Track: Biotech
Time / Date: 11.30, Day 1, 5th February
Room: Private Dining
Target Market: Oncology
Description: STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer.
Stage: Early growth
Ownership: Private
Country: UK



Presenter: Gregory Mario, CEO
Track: Biotech
Time / Date: 11.45, Day 2, 6th February
Room: Private Dining
Target Market: Infectious disease
Description: Expanding its portfolio of drug candidates by focusing on addressing elemental drug resistance mechanisms to reduce, or possibly eliminate, the threat of current and emerging antibiotic resistance across a wide-range of infectious diseases.
Stage: Early growth
Ownership: Private
Country: USA



Presenter: Luc Dochez, CEO
Track: Biotech
Time / Date: 11.30, Day 2, 6th February
Room: Private Dining
Target Market: Immunology, oncology
Description: Development of novel immune modulating antibodies based on in-depth understanding of the immune system.
Stage: Early growth
Ownership: Private
Country: UK



Presenter: Fred Jacobs, CEO
Track: Biotech
Time / Date: 2.00, Day 1, 5th February
Room: Private Dining
Target Market: Gastroenterology, immunology, metabolic disease, oncology, vaccines, mAbs
Description: Develops novel therapeutic vaccines to treat gastric cancers. TYG's vaccines are based on a unique, proprietary technology platform.
Stage: Early growth
Ownership: Private
Country: UK



Presenter: Cameron Reynolds, CEO
Track: Medtech
Time / Date: 2.45, Day 1, 5th February
Room: Specialist
Target Market: Oncology
Description: Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers.
Stage: Late growth
Ownership: Public (NYSE)
Country: UK

MEDIA PARTNERS




ATTENDING COMPANIES


28 North Discovery	Coulter Partners	Imperium Capital	Oxford AHSN
4BIO Capital	Covington & Burling	Inceptua	Oxford BioMedica
4D pharma	CRB Inverbio	Industrifonden	Oxford Technology Management
45C	Crescendo Biologics Ltd	InflaRx GmbH	Oxford University Innovation
Abingworth	Crescent Enterprises	Informa Group	Oxon
Ablynx	CRISPR Therapeutics Limited	InHealth Ventures	OxSonic
Accelerace	CTI Life Sciences	INKEF Capital	OxStem
Acceleris Capital	Curam Capital Management	Inmedix	Panakes Partners
Accelmed	Cyralis Ltd.	Innogest	Panmure Gordon
Active Needle Technology	Da Volterra	Inserm Transfert	Paul Capital
Addex Therapeutics	DDF Ventures	Inserm Transfert Initiative / Sofimac	PCI Biotech
AdRem Capital	DeBere Capital Partners	Instinctif Partners	Pentracor
Advent France Biotechnology	Deepbridge Capital	InterAx Biotech	Peppermint Venture Partners
Advent Life Sciences	Dementia Discovery Fund	Interceptin	Perora GmbH
Advokatfirman Vinge KB	Destiny Pharma	Inventages	Pfizer
Aglaris	Diamond Biopharm	Invest Newcastle	PhagoMed Biopharma
AKL	DN Capital	IO Biotech	PharmaVentures
Alacrita Consulting	Downing	IP Group	Pharmstandard Ventures
Albion Capital	DSM Venturing	IPF Partners	PI Trading
Albion Technology & General VCT	Duke Street	ISA Pharmaceuticals BV	Poul Schmith
Alderley Park Ventures	Dyadic	ISIF	Primer Capital
Allegra Therapeutics GmbH	Dynasty Biotechnology & The Sino-UK Fund	Ivaldi Capital	Principia SGR
Allen & Overy	e-Therapeutics	J O Hambro Capital Management	Privos Capital (Multi-Family Office LP)
Amadeus Capital Partners	Earlybird Venture Capital	JAG Shaw Baker	Probiobdrug AG
Angel Investor	Edison	Jefferies	Proteome Sciences Plc
Antabio	Edmond de Rothschild Investment Partners	Johnson & Johnson Innovation	PsiOxus Therapeutics
Apeiron Biologics	Eli Lilly & Co.	JPI Fund	Q-linea AB
Ardian	Eli Lilly and Company	JSC Pharmstandard	Rainbow Seed Fund
Arecor	EMD Serono	Julz Co	RBC Capital Markets
Arix Bioscience	Enesi Pharma	Karolinska Development	RBV Capital
Arterial Capital Management	Enterprise Ireland	Keiretsu Forum	Re-Pharm
Arthurian Life Sciences	Entrust People	Kiadis Pharma	Reaplix
Artios Pharma	EP Vantage	King's College London	RedEye
Asarina Pharma	Epi-Endo Pharmaceuticals	Kinled Holding	Renephra Ltd.
Astex Pharmaceuticals	Epidarex Capital	Kreos Capital	ReNeuron
Astraveus	EpiMab Biotherapeutics	Kurma Partners	Renovos Biologics
AstraZeneca	Ergomed	Laurel Venture Capital	Rigontec
Atelix	Esperante	Leerink Partners	RMI Partners
Atlantic Bridge	Eternans Limited	LifeArc	Rosetta Capital
Atlantic Therapeutics	Ethris GmbH	LIG Biowise	Rothschild
Atropa Therapeutics	Eurocine Vaccines	Limerston Capital	RYSE Asset Management
ATXA Therapeutics Ltd	Euronext	LipoCoat BV	Sanara Ventures
Aurora-TT	European Investment Bank	Longevity Venture Partners	Scancell Holdings
Auspherix	European Investment Fund	Longwall Venture Partners	Scientific Protein Labs
Avego Healthcare Capital	Exonate Ltd	Lonza	SCRIP
AVM Biotechnology	EY	Magle Chemoswed	Selvita
Balmes Transplantation	F-Prime Capital	MangoGen Pharma	Senzime
Baxter	F-star Biotechnology	Marks & Clerk	Seroba Life Sciences
Belsize Asset Management	Femeda	Masselos Family Office	Shore Capital
BioArctic AB	Fiagon	MC Services	Siemens Healthineers
BioGeneration Ventures	Fieldhouse Associates	McLaren Applied Technologies	Silence Therapeutics
BioProtect Ltd.	Financial Times	Medherant	Simply Capital Partners
Biosana Pharma	Flagship Pioneering	Medixi	Sixth Element Capital
BioScience Managers	Flowsion A/S	Medivir	SJB Technical Recruitment Ltd
BioSeed Capital	FOLIUM Food Science Limited	Medlumics	Sofinnova Partners
Biosignatures	Forbes	Medtech Insight	SOM Biotech
Biotech and Money	Forbion Capital Partners	Medtronic	SPARK Impact
BioTissue SA	Fountain Healthcare Partners	MEDX Xelerator	Sphere Medical
Biovotion	FreeMind Group	Meneldor	SR-One
Blueprint Genetics	Fresenius Medical Care Ventures	Mercia Technologies	Stifel
Boehringer Ingelheim	FTI Consulting	Merck Ventures	Storm Therapeutics
Bone Support	Fund Twenty8	MetaLinear	Summit Therapeutics
Bone Therapeutics	Future Care Capital	Mironid	Sunstone Life Science Ventures
Bonsai Capital	Galapagos	MISSION Therapeutics	Surgacoll Technologies
Boston Scientific	Galecto Biotech	Mologen	SV Health Investors
Boston Scientific Ventures	Genentech Partnering	Momentum Biotech	SwabTech Limited
Boult Wade Tennant	GIC	MonTa Biosciences	Syncona Ltd.
Bpifrance	Gilde Healthcare	Montagu	SyndicateRoom Growth Fund
BrainWaveBank	Gill Jennings & Every	MorphoSys	Takeda
BRASTER S.A.	GIMV	MSD	Talentmark
Bridge Biotec	Global Core Medical	MSIF	Tassi & Co.
British Expats in Life Sciences	GlobalData	MTIP	TAXIS Pharmaceuticals
Brothers & Partners Europe	Goldman Sachs	MVM Partners	The Side by Side Partnership
Brown Rudnick	Goodwin Procter	MXC Capital	Tillotts Pharma AG
Calcvix	Graphite Capital	N+1 Singer	Topas Therapeutics
Cambridge Angels	GSK	NASDAQ	TPBioVentures Ltd
Cambridge Enterprise	H.C. Wainright	NCL Technology Ventures	Trilantic Europe
Cambridge Innovation Capital	Hadasit Medical Research Services and Development	NeoMed	Trinity Delta
Cambridge Medical Robotics	Hadean Ventures	NetScientific	Tusk Therapeutics
Cambridge Medical Technologies	Hansa Medical	New Science Global Healthcare Fund	TVM Capital Life Science
Cancer Research UK	Harbert European Growth Capital	New Wave Ventures	TYG-Oncology
Cantargia AB	Haseltine Lake	Newable Private Investing	UCB Pharma
Capital Cell	HBM Partners	Norgine Ventures	UCB Ventures
Capricorn Venture Partners	Health Equity Consulting	North-East Healthcare Investment	UMIP
Cardiorientis	Health Ventures	Nova Leah	Universitat Autònoma de Barcelona
Carmell Therapeutics	HealthCap	Novacyt	University of Dundee
Carnegie Investment Bank	HealthCare Royalty Partners	Novintum Bioscience	University of Edinburgh
Catapult Digital	Heat Biologics	Novo Holdings	University of Southampton
Catapult Ventures	Heptares Therapeutics	Novo Ventures	ValiRx Plc
Celgene	Herantis Pharma	NOXXON Pharma	Ventac Partners
Celixir plc	Hermes Partners Intl.	NY Consulting	VentureFounders
Cell & Gene Therapy Catapult	High-Tech Gründerfonds	O2h Ventures Limited	Verona Pharma
Chronos Therapeutics	Hogan Lovells	Oisin Biotechnologies	Vita Advisory
Citi Depositary Receipt Services	Hogan Lovells	Olympus Europa	Vivet Therapeutics
Citigate Dewe Rogerson	Hookipa Biotech	Omnes Capital	VolitionRx
ClearlySo	Horizon Discovery Group	Oncimmune plc	Waimangu Ventures
Clinigen Group	Idogen	OncoGenesis	West Hill
Clubb Capital	IGEM Therapeutics	Oncology Venture	Wharton Alumni Angel Network
CMS Cameron McKenna Nabarro Olswang LLP	Ignite Capital Partners	Oncopeptides	Wharton Asset Management
CN Bio Innovations	Illumina Ventures	Optimum Communications	White & Case LLP
co.don	Image Analysis Group (IAG)	OR Productivity	WideCells Group
Cocoon Networks	Immersive Rehab	OrbiMed	Wren Capital
Cole Capital	Immunicum	Orca Therapeutics	Zillico Limited
Consilium Strategic Communications	Immunocore	Ostara Biomedical	ZOLL Medical, an Asahi Kasei Group Company
Cook Regentec	Imperial Innovations	Ostoform	Zonda Partners
Cooley		OvuSense	Zukunftsfonds Heilbronn

CONGRESS FLOORPLAN

FIRST FLOOR



UPPER GROUND FLOOR





WEB

[www.biotechandmoney.com/
world-congress](http://www.biotechandmoney.com/world-congress)

SILVER PARTNERS



ASSOCIATE PARTNERS

